65
Participants
Start Date
April 25, 2015
Primary Completion Date
July 25, 2023
Study Completion Date
December 20, 2023
Abatacept
Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .
placebo
Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.
Hospital for Special Surgery, New York
University of Pennsylvania, Philadelphia
University of South Florida Rheumatology, Tampa
Vanderbilt University, Nashville
Cleveland Clinic, Cleveland
University of Michigan, Ann Arbor
Mayo Clinic Rochester, Rochester
University of Kansas Medical Center, Kansas City
Medius Kliniken, Kirchheim unter Teck
Cedars Sinai Medical Center, Los Angeles, Los Angeles
Oregon Health & Science University, Portland
University of Calgary, Calgary
University of British Columbia, St. Paul's Rheumatology Clinic, Vancouver
St. Joseph's Hospital, Hamilton, Hamilton
St. Vincent's University Hospital, Dublin
University of Cambridge- Addenbrookes Hospital, Cambridge
Mount Sinai Hospital, Toronto, Toronto
University of Aberdeen, Aberdeen
Nottingham University Hospitals, Nottingham
Royal Berkshire Hospital, Reading
Collaborators (1)
The Cleveland Clinic
OTHER
Bristol-Myers Squibb
INDUSTRY
University of Pennsylvania
OTHER
National Institutes of Health (NIH)
NIH
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
University of South Florida
OTHER